SAB Biotherapeutics Strengthens Board of Directors with Appointment of Biotech Veteran
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today announced that Thorkil Kastberg Christensen has joined their Board of Directors. SAB, which was founded in 2014, develops human antibody therapeutics using its first-of-its-kind immunotherapy platform.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170426006134/en/
Thorkil Kastberg Christensen (Photo provided by Thorkil K. Christensen)
Christensen brings to SAB decades of global business strategy and execution as former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about US$40 billion. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations.
“SAB’s technology is a platform for development of better and more effective medicines in many areas with unmet needs,” said Thorkil Kastberg Christensen. “This is at the heart of what I have been doing most of my life and I am happy to be able contribute,” he added.
Currently, Christensen serves as advisor for Novo A/S and a professional board member for Strategic Design Group and Sonion A/S among others. Since 2009, he has held additional board positions with private and publicly listed companies, in Denmark, abroad, and in public institutions including Chairman of the board of Danish-Chinese Business Forum, Jørgen Kruuse A/S and BioMimetics Inc., USA.
For SAB, Christensen has served as a strategic international business advisor since July of 2015.
“Mr. Christensen has been a trusted advisor and asset to SAB as we have advanced our technology and expanded collaborations within the U.S. and globally,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics.
“His experience with financing, technology deployment and his network with leading public health, biotech and Pharma organizations will be valuable to the board as we continue to build our footprint and portfolio,” he added.
As a proven leader in life science business, Christensen has specialized in internationalization, as well as mergers, acquisitions, and other transactions. This work includes building organizations, transforming companies from R&D to commercial focus, and adding value to growing companies.
“The possibilities for using human antibodies, and polyclonals in particular, for the benefit of mankind are endless and in many areas there are great commercial potentials as well,” said Christensen. “I look forward to working closer with the colleagues at SAB in striving to realize some of these potentials.”
SAB is developing products for several targets including seasonal influenza, mycoplasma, C-Diff, Zika and Ebola. In addition, a Phase I Clinical Trial with the National Institutes of Health for its treatment for MERS-CoV is nearly complete and has funding support from BARDA for Phase 2.
In 2016 SAB’s novel immunotherapy platform was recognized by the World Health Organization as the most promising therapeutic platform technology to combat priority pathogens as well as other diseases with epidemic potential.
“With the unique capability of our technology platform in its ability to rapidly respond to various life-threatening diseases, our business is a global one,” added Sullivan. “Leveraging Mr. Christensen’s experience and expertise will only strengthen our capability to bring life-saving therapies to people in countries around the world.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science in the world, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cushman & Wakefield To Acquire Its Irish Affiliate From Sherry FitzGerald Group16.7.2018 13:49 | Pressemelding
Global real estate services firm Cushman & Wakefield today announces it has entered into a definitive agreement to acquire the commercial property arm of Sherry FitzGerald Group in the Republic of Ireland. The deal is expected to complete in early September 2018. Cushman & Wakefield already has a 20% stake in the Irish commercial property business which operated as its exclusive affiliate in the Republic – rebranding two years ago as Cushman & Wakefield Ireland. The firm, which has more than 100 commercial property professionals and offices in Dublin, Limerick and Galway, will now be fully integrated into Cushman & Wakefield, one of the world’s largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. Managing Director Aidan Gavin becomes Cushman & Wakefield’s Head of Ireland and will also sit on the firm’s UK & Ireland Executive Committee. Cushman & Wakefield will maintain its close affiliate relationship with the wider Sherry FitzGerald G
Fischer & Schickendantz and Solution Alliance SRL Adopt Andersen Brand in Uruguay16.7.2018 13:30 | Pressemelding
Fischer & Schickendantz, led by Juan Federico Fischer, and Solution Alliance SRL, led by Juan Ignacio Troccoli, have rebranded this week as Andersen Tax & Legal, a member firm of Andersen Global. The firm, based in Montevideo, entered a Collaboration Agreement with Andersen Global in September 2017, and is now a fully integrated member of the global verein. Juan Federico Fischer remarked, “Andersen is a symbol of quality and is recognized worldwide by both clients and professionals, and is ahead of the game in terms of creating a global firm with integrated tax and legal services. We are truly excited to officially be part of the team.” “Throughout their time with us as a collaborating firm and now a member firm, the team in Uruguay has demonstrated a deep commitment to providing seamless, best-in-class service. Additionally, Juan Federico is a member of Andersen Global’s Latin American regional board, and is the true embodiment of the values that our organization represents. I look fo
Norsk Titanium Produces Space Demonstration Hardware16.7.2018 11:00 | Pressemelding
Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, has produced an Expansion Nozzle demonstrator in support of the European Space Agency’s Technology Research Programme (TRP). The TRP is an European Space Agency (ESA) technology development effort supporting all of ESA’s fields of activity across the entire spectrum of technical disciplines, providing the technological nucleus for most future developments. Norsk was awarded a TRP contract with the ESA in 2014 to explore the application of Norsk’s Rapid Plasma Deposition™ (RPD™) process to space applications. Through the TRP contract, Norsk has refined its material characterization and quality assurance processes, while providing ESA valuable insight into the application of additive processes to their unique needs. The culmination of this effort was the production of an Expansion Nozzle demonstrator. The Expansion Nozzle utilizes the latest RPD™ desi
CALVIN KLEIN Fragrances Announces Lupita Nyong'o and Saoirse Ronan as Faces of CALVIN KLEIN WOMEN16.7.2018 11:00 | Pressemelding
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE:COTY], today revealed the worldwide print advertising campaign for the new fragrance CALVIN KLEIN WOMEN , the first CALVIN KLEIN fragrance to be developed under the vision of Chief Creative Officer, Raf Simons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005092/en/ CALVIN KLEIN WOMEN The campaign features Lupita Nyong'o and Saoirse Ronan. Award-winning actors and voices of their generation, both women are universally recognized for their unique talent, creativity, intelligence and strength of character. Directed by artist Anne Collier with creative direction from Lloyd & Co., the campaign champions iconic women and celebrates heroines of contemporary culture. Lupita and Saoirse are featured in the print campaign, in a pair of striking and direct portraits, positioned next to chosen figure
Bank of America Reports Second-Quarter 2018 Financial Results16.7.2018 10:45 | Pressemelding
Bank of America reported its second-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005280/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference ca
Bank of Singapore is the First Singapore Private Bank to Receive Regulatory Approval to Open a Wealth Management Subsidiary in Luxembourg16.7.2018 09:36 | Pressemelding
Bank of Singapore today announced that it has been granted an investment company licence to operate a wealth management subsidiary in Luxembourg – a first for a Singapore private bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005252/en/ (Photo: BOSWM) Bank of Singapore, through this new subsidiary, BOS Wealth Management Europe Société Anonyme (S.A.), will be able to offer a comprehensive range of customised private banking solutions and investment advisory services to its ultra-high and high net worth clients in the European Economic Area (“EEA”) and the United Kingdom (“UK”). The EEA comprises the European Union (EU) countries and Iceland, Liechtenstein and Norway. Currently, Bank of Singapore serves its European clients from its Singapore headquarters and through its parent company OCBC Bank’s London office. There has been robust growth in assets under management from EEA clients as they hold Singapore in high